A Note From CanceRx
As we step into 2026, we are reflecting on a landmark year of growth. In this update, we dive into the systematic barriers holding back cancer research, the innovative funding model we've built to break through them, and the momentum we're carrying forward from our 2025 breakthroughs.
Closing the Gap |
The goal is simple: help credible research survive the hardest part of development and reach patients. |
CanceRx exists to solve a problem that remains largely invisible. In oncology, promising therapies often fail, not because the science is weak, but because funding runs out exactly as they enter human clinical trials. Clinical trials are costly, extensive and nearly impossible to progressively finance through traditional channels.
As a result, promising cures are interrupted for years or abandoned entirely.
CanceRx was created to address this gap. Our model focuses on providing long-duration, stable funding across a diversified set of US-based cancer clinical trials. Funding designed to match the pace of science, not the demands of quarterly returns.
Instead of betting on a single breakthrough, we finance portfolios of trials across diverse cancer types and mechanisms. By spreading the risk, we ensure that good science isn’t lost to short-term capital constraints.
The goal is simple: help credible research survive the hardest part of development and reach patients.